Introduction to ESMO 2025 Genitourinary Cancer Abstracts ESMO 2025 genitourinary cancer abstracts show exciting new finds. For instance, they include…
Browsing: immunotherapy
Immune checkpoint inhibitors myocarditis poses a serious threat in cancer care. These drugs fight tumors well. However, they can inflame…
Introduction to Neoadjuvant Therapy for Melanoma Neoadjuvant therapy is changing how we treat melanoma, offering big benefits over traditional adjuvant…
On September 6, 2025, at the MOASC and ANCO Immuno-Oncology Symposium, Dr. Alexis LeVee, MD, from UCLA’s Division of Hematology/Oncology,…
ASCO 2025 and the MOASC Conference unveiled major progress in colon cancer treatment advancements. For example, the CHALLENGE study showed…
OncologyTube brings you an exclusive look at the AMPLIFY-201 Phase 1 trial. Furthermore, this study highlights ELI-002 2P, a lymph…
The Matterhorn Trial, a landmark phase III study published in the New England Journal of Medicine, evaluates durvalumab, an anti-PD-L1…
The ASCO 2025 conference, held recently, shared new research that may shape cancer treatments. This article covers studies on treatment-induced…
Digestive cancers therapeutics takes center stage as these cancers—esophageal, gastric, biliary, pancreatic, hepatocellular, and colorectal—account for 33-35% of global cancer…
At the 2025 ASCO Annual Meeting, new data on IO-based combinations in mRCC emerged. For instance, Dr. Brian Rini, MD…
Published: June 4, 2025Category: Lung Cancer Research Introduction to Neoadjuvant Nivolumab Plus Chemotherapy in CheckMate 816 The CheckMate 816 trial…
At the 2025 ASCO Annual Meeting, a phase 3 randomized trial revealed that the timing of immunotherapy in non-small cell…
A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data…
Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s…
Could 2025 Oncology Have Saved Steve Jobs from Pancreatic Cancer? A Deep Dive into Past and Future Treatments February 21,…
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At…
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD,…
Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer…
Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients…
Abstract: Circulating tumor DNA (ctDNA) has a short half-life (<2 hours) which may permit real-time monitoring of tumor status. This…
In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP) via liquid biopsy has become…
We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.
The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical…
On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of…
Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or…
On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…
Introduction ASCO 2024 Head & Neck Cancer developments brought forth several anticipated studies. These studies in the field of head…
Author: Dr. Alexis LeVee, City of Hope At the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented…
Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour,…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered…
Presented By: Shirin Attarian, MD Date Aug 12, 2023 In the realm of oncology, Head and Neck Cancer stands as…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in…
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics By Jeff Liter, MBS, CEO of Luminary…
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell…
Urothelial Cancer: What’s New in 2023? Targeted and Novel Therapies Nataliya Mar MD By Nataliya Mar, MD Good afternoon, everyone.…
How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD…
iFrame is not supported! Inotuzumab and MRD Understanding the Importance of Targeted Therapy in Cancer Treatment Summarized from Van Huynh,…
MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at…
Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia…
LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed…
PRO in Pts With Rare Cancers: Pembrolizumab [2022] Â Patient reported Outcome (PRO) in patients with rare cancers (rare diseases)…
Follow real-world patients on their cancer journeys as they and their multidisciplinary clinical teams navigate barriers to receiving treatment with…
In this edition of The Onco’Zine Brief, Peter Hofland talking with Helen Sabzevari, the president of Precigen. Precigen is a…